Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

By M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire, F. Ducray, S. El Hallani, B. Boisselier, K. Mokhtari, K. Hoang-Xuan and 1 more. Journal of Clinical Oncology, 2009

973 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Neurology

View Paper: https://www.semanticscholar.org/paper/93c621f8a17a3853a51e3fb9929da50233f9f058

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

Citations in the corpus

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Indeed, the survival of IDH-mutated GBM is more favourable than for non-mutated grade III astrocytoma, thus underscoring the strong prognostic value of this finding [10, 12].”
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (2010, background): “Interestingly, G-CIMP tumors displayed copy-number alterations that were also shown in gliomas with IDH1 mutations in a recent report (Sanson et al., 2009).”
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations (2010, background): “…on outcome, the finding that 4/4 patients retained the mutation upon relapse suggests that it is stable through the course of disease progression, and may be clinically useful as a marker of minimal residual disease, as has been shown for nucleophosmin 1 (NPM1) mutations (Schnittger et al., 2009).”
Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “In addition to providing insights about the origin of gliomas, the mutational status of IDH1/2 serves as a prognostic marker in patients with WHO grade II and III gliomas [58, 123, 141, 181] and GBMs [172].”
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma (2010, background): “Additionally, IDH mutations areassociated with other genomic abnormalities that are typically seen in lower grade diffuse gliomas, such as TP53 mutation and 1p/19q deletion; they are also mutually exclusive with EGFR amplification and chromosome 10loss, and multivariate analysis suggests that ”
Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “They predict improved overall survival, independently of other prognostic factors [83], and they are more prevalent in long-term survivors [84].”